BioRay Announces First-Patient-In for Phase I Clinical Study of BRY812, a Novel LIV-1 Targeting Antibody Drug Conjugate

BioRay Pharmaceutical Co., Ltd. announced that the first patient has been dosed in the Phase I Clinical trial of BRY812, a third-generation antibody-drug conjugate targeting LIV-1 for the treatment of advanced malignant tumors.